As in previous brigatinib studies, the most common AEs in this J-ALTA cohort included elevated CPK, hypertension, elevated amylase, elevated lipase, hepatic enzyme abnormalities, and gastrointestinal AEs. The gene discussed is PIK3C2A; the disease is hypertensive disorder.